CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Capricor Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Capricor Therapeutics Inc
10865 Road to the Cure, Suite 150
Phone: (302) 658-7581p:302 658-7581 SAN DIEGO, CA  92121  United States Ticker: CAPRCAPR
Business Summary
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Frank I.Litvack 70 1/1/2016 9/24/2009
President, Chief Executive Officer and Director LindaMarban 62 1/1/2014 11/21/2013
Chief Financial Officer AnthonyBergmann 40 1/1/2018 11/22/2013
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Capricor, Inc. 8700 Beverly Boulevard Los Angeles CA United States

Business Names
Business Name
CAPR
Capricor Therapeutics, Inc.
Capricor, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 231 (As of 12/31/2025)
Outstanding Shares: 57,911,893 (As of 5/11/2026)
Shareholders: 112
Stock Exchange: NASD
Federal Tax Id: 880363465
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 15, 2026